Vittoria Biotherapeutics recently received approval from the U.S. Food and Drug Administration (FDA) to proceed with a Phase 1 clinical trial for VIPER-101, their primary candidate treatment. VIPER-101 is a gene-edited, personalized CAR-T cell therapy designed to address patients’ relapsed or refractory T-cell lymphoma.
In a recent announcement, Vittoria’s CEO, Dr. Nicholas Siciliano, highlighted the FDA’s green light for their VIPER-101 drug. Given the minimal progress in T-cell lymphoma treatments over the past ten years, this achievement represents a crucial stride toward introducing a groundbreaking treatment option for T-cell lymphoma patients. This opportunity arises from their unique Senza5 platform technology, which aims to elevate effectiveness and safety in treatments.
Dr. Marco Ruella, scientific co-founder of Vittoria and an assistant professor at the University of Pennsylvania’s Perelman School of Medicine, emphasized the pressing need for new therapies in T-cell lymphoma treatment. He expressed satisfaction in advancing VIPER-101, the initial cell therapy stemming from their innovative Senza5 technology, into human trials.
VIPER-101 is the primary autologous CD5-targeting therapy, aiming to address challenges like fratricide, bolster anti-tumor effectiveness, and alleviate safety concerns inherent in CAR-T therapies targeting T-cell malignancies.
Source: Vittoria Biotherapeutics Announces FDA Clearance of IND Application for VIPER-101 to Treat T-Cell Lymphoma
https://finance.yahoo.com/news/vittoria-biotherapeutics-announces-fda-clearance-130000463.html
